

ASX Release

18th November 2014

PHARMAUST IN RESEARCH COLLABORATION AND JOINT PATENT WITH JAPANESE COMPANY

PharmAust Limited (“PharmAust”) (ASX: PAA & PAAO) is pleased to report that further to signing a Materials Transfer Agreement (MTA) with a yet to be named Japanese Corporation in July 2013, it has now established a joint intellectual property (IP) position with this Japanese partner. The joint IP allows PharmAust access to some 80 analogues of PPL-1, which have been synthesised by the Japanese research partner and tested for anticancer activity by PharmAust. The Joint Patent Application, which will be published in March 2015, further permits PharmAust to commercialise the analogues subject to other prevailing IP at the time of commercialisation. This collaboration broadens and strengthens PharmAust’s IP position.

PharmAust’s Executive Chairman, Dr Roger Aston said, “The commercialisation of aminoacetonitriles in cancer, of which PPL-1 is a key approved product for treatment of veterinary parasites, is PharmAust’s principal activity at the present time. Both the current dog trial and the human trial underway in NSW and SA respectively are targeting cancer under circumstances where the recipient has failed all standards of care. Success in either or both of these trials will be a key driver for commercial development of anticancer drugs based on the aminoacetonitrile class of drug and in the forging of alliances to commercialise such products. PharmAust currently has a Collaborative Research and Option Agreement with one of the top five major global pharmaceutical companies for the development and commercialization of PPL-1 in veterinary cancers.”

The cancer chemotherapy market (estimated at \$42 billion/annum)* is currently the fastest growing sector within the pharmaceutical industry, mainly driven by the identification of new potential therapeutic targets. This growth is further fuelled by the magnitude of the disease worldwide, currently estimated at more than 25 million people suffering from cancer globally, and an estimated 5 million people dying each year from the disease.

*Reference: Research and Markets.com accessed 14th February 2014:
http://www.researchandmarkets.com/reports/335548/chemotherapy_market_insights_20062016_a

For further details please contact:

Dr Roger Aston
Executive Chairman
PharmAust Limited
Tel: 0402 762 204

www.pharmaust.com